Ontario

Ministry of Health
Drugs and Devices Division

# Executive Officer Notice: Brand Reference Price Regulations Amendment

April 23, 2020

Notice to Drug Manufacturers

The purpose of this notice is to provide an update about regulatory amendments under the *Ontario Drug Benefit Act* relating to brand reference prices that came into force on April 1, 2020. The regulatory amendments are available here: https://www.ontario.ca/laws/regulation/r20123

Manufacturers are asked to take note of the following:

**There is no change to the multiple source drug product submission and formulary price confirmation process for all new drug products seeking consideration for funding under the Ontario Drug Benefit (ODB) Formulary. Manufacturers must follow the same established process.** Manufacturers must continue to apply to the pan-Canadian Pharmaceutical Alliance for price confirmation and submit the approved Market Entry price assessment form to the ministry as usual. The ministry will consider the drug products taking into account the regulatory amendments noted above.

If you have an existing multiple source drug product which you believe may qualify for funding consideration as a result of the regulatory amendments, you may request a review by providing a full submission to the ministry following the same process as for new multiple source drug products.

General inquiries regarding drug submissions, review process, and product listing may also be sent to: PCPA-Generics-ON@ontario.ca.

Thank you for your understanding and co-operation.